ArticleFrontiers in oncology2026
Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multidrug resistance (MDR) critically limits doxorubicin (Dox) efficacy in glioma. To overcome this, we constructed a folic acid receptor (FAR)-targeted liposomal system for codelivering Dox and curcumin (Cur). Methods: Dox/Cur-Lip@FA was prepared using the film hydration-sonication method. The physicochemical properties (size, zeta potential, encapsulation efficiency, and drug release) were characterized. The studies assessed P-gp modulation and cellular uptake in Dox-resistant C6 cells, as well as Results: The FA ligand enabled selective tumor targeting by binding to overexpressed FAR, while Cur enhanced Dox efficacy by downregulating P-gp-mediated drug efflux. Dox/Cur-Lip@FA exhibited a uniform size of 112.5 ± 3.8 nm, a zeta potential of -7.85 ± 0.62 mV, high dual-drug EE% (Dox: 91.32 ± 3.95%; Cur: 90.87 ± 4.21%), and sustained release kinetics. Conclusion: This FA-functionalized codelivery system combines active targeting with MDR reversal, showing improved cellular uptake
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.